Showing results (91-100 of 230) with videos related to
Sort By:
Pageof 23
British Journal of Cancer|June 27, 2022
Pre-diagnosis and post-diagnosis dietary patterns and survival in women with ovarian cancerNaoko Sasamoto, Tianyi Wang, Mary K Townsend, et al.Gynecologic Oncology|November 20, 2009
Phase II trial of GM-CSF in women with asymptomatic recurrent müllerian tumorsMaria R Roche, Pandora J Rudd, Carolyn N Krasner, et al.Gynecologic Oncology|July 19, 2005
A6, a urokinase plasminogen activator (uPA)-derived peptide in patients with advanced gynecologic cancer: a phase I trialAnna Berkenblit, Ursula A Matulonis, Joan F Kroener, et al.The European Journal of Neuroscience|November 19, 2003
Effect of NT-4 and BDNF delivery to damaged sciatic nerves on phenotypic recovery of fast and slow muscles fibresMagda Simon, Rebecca Porter, Robert Brown, et al.International Journal of Microbiology|December 24, 2011
Q Fever: current state of knowledge and perspectives of research of a neglected zoonosisSarah Rebecca Porter, Guy Czaplicki, Jacques Mainil, et al.Journal of Cancer Research and Clinical Oncology|November 21, 2019
Transcriptome analysis reveals overlap in fusion genes in a phase I clinical cohort of TNBC and HGSOC patients treated with buparlisib and olaparibJulia Eismann, Yujing J Heng, Johannes M Waldschmidt, et al.Gynecologic Oncology|August 28, 2017
Characterization of folate receptor alpha (FRα) expression in archival tumor and biopsy samples from relapsed epithelial ovarian cancer patients: A phase I expansion study of the FRα-targeting antibody-drug conjugate mirvetuximab soravtansineLainie P Martin, Jason A Konner, Kathleen N Moore, et al.Gynecologic Oncology|March 19, 2021
Incidence of myelodysplastic syndrome and acute myeloid leukemia in patients receiving poly-ADP ribose polymerase inhibitors for the treatment of solid tumors: A meta-analysis of randomized trialsRoni Nitecki, Alexander Melamed, Allison A Gockley, et al.Gynecologic Oncology|July 23, 2025
Safety and efficacy of mirvetuximab soravtansine, a folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC), in combination with pembrolizumab in patients with platinum-resistant ovarian cancerUrsula A Matulonis, Ignace Vergote, Kathleen N Moore, et al.Gynecologic Oncology|February 16, 2012
Changes in serum CA-125 can predict optimal cytoreduction to no gross residual disease in patients with advanced stage ovarian cancer treated with neoadjuvant chemotherapyNoah Rodriguez, J Alejandro Rauh-Hain, Melina Shoni, et al.Pageof 23